A new material for treatment of single receding gums

Clinical comparison of coronally-advanced flap plus Xenogeneic Porcine-derived acellular dermal Matrix (Botiss Mucoderm®) and subepithelial connective tissue graft in the treatment of single tooth recessions

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15571664

Enrollment

Registered

2022-01-24

Start date

2021-09-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival recession Oral Health

Interventions

Participants defects will be randomly divided into two groups by obaque sealed invelope method: control group (will be treated with Coronal Advanced Flap (CAF) + subepithelial Connective Tissue Graft

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Good general health. 2. No contraindications for periodontal surgery. 3. Presence one localized gingival recession in each side of the maxilla and/or mandible, All recessions will be Class I or II defects (Miller 1985). 4. The cemento–enamel junction (CEJ) will be visible in the teeth for root coverage procedures. 5. All patients demonstrating adequate plaque control. 6. All patients will be at least 18 years of age. 7. No previous periodontal surgery in the area.

Exclusion criteria

Exclusion criteria: 1. Patients smoking more than 10 cigarettes per day. 2. Patients with insulin-dependent diabetes. 3. Patients with a history of malignancy, radiotherapy, or chemotherapy for malignancy. 4. Patient pregnant or nursing during the past 5 months. 5. Patients taking medications or having treatments with an effect on mucosal healing in general (e.g. steroids, large doses of anti inflammatory drugs). 6. Patients with a disease affecting connective tissue metabolism. 7. Patients allergic to collagen. 8. Presence more than one localized gingival recession in each side of the maxilla and/or mandible.

Design outcomes

Primary

Measure	Time frame
1. Gingival recession depth measured using a UNC-15 probe at baseline, 1, 3, 6 months 2. Gingival recession width measured using a UNC-15 probe at baseline, 1, 3, 6 months 3. Keratinized Tissue Thickness measured using an anesthesia needle attached to a silicone disc stop at base line, 3 , 6 months.	—

Secondary

Measure	Time frame
1. Probing depth measured using a UNC-15 probe at baseline, 3, 6 months 2. Relative attachment level measured using a UNC-15 probe at baseline, 3, 6 months 3. Keratinized tissue height measured using a UNC-15 probe at baseline, 3, 6 months 4. Healing measured using a healing index at 1, 2 weeks and 1 month after surgery 5. Plaque presence measured using a plaque index at baseline, 1, 3, 6, months 6. Pain measured using a visual analogue scale (VAS) at 1 week after surgery 7. Bleeding measured using a visual analogue scale (VAS) at 1 week after surgery 8. Dentine hypersensitivity measured using a visual analogue scale (VAS) at baseline, 1, 3, 6 months	—

Measure

Time frame

1. Probing depth measured using a UNC-15 probe at baseline, 3, 6 months 2. Relative attachment level measured using a UNC-15 probe at baseline, 3, 6 months 3. Keratinized tissue height measured using a UNC-15 probe at baseline, 3, 6 months 4. Healing measured using a healing index at 1, 2 weeks and 1 month after surgery 5. Plaque presence measured using a plaque index at baseline, 1, 3, 6, months 6. Pain measured using a visual analogue scale (VAS) at 1 week after surgery 7. Bleeding measured using a visual analogue scale (VAS) at 1 week after surgery 8. Dentine hypersensitivity measured using a visual analogue scale (VAS) at baseline, 1, 3, 6 months

—

Countries

Syria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026